How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

634 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles

Questionnaire on Dark Circles, Medical History, and Lifestyle Habits [ Time Frame: Day 1 ] The Subject Questionnaire on Dark Circles, Medical History and Lifestyle Habits is a 15-item questionnaire completed by the participant. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor (...) to the study visit appointment Willingness to cleanse the face and remove all makeup at least 15 minutes prior to each scheduled clinic visit Willingness to have facial exams, skin instrumentation measurements, and digital photos performed on the face. Exclusion Criteria: Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring, tattoos, or other skin conditions in the test area Uncontrolled disease

2018 Clinical Trials

162. Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment) Willing to follow abstinence requirements for the duration of study participation (See the protocol for additional information) For participants of childbearing potential: a negative pregnancy test at Screening and Enrollment For participants of childbearing potential: Per participant report at Enrollment, using an effective method (...) months prior to Enrollment Non-therapeutic injection drug use in the 12 months prior to Enrollment Participation in research studies involving drugs, medical devices, genital or rectal products, or vaccines within 30 days of the Enrollment Visit Gynecologic, genital, or rectal procedure (e.g., tubal ligation, dilation and curettage, piercing, hemorrhoidal resection, polyp removal) 60 days or less prior to Enrollment, or rectal biopsy, 7 days or less prior to Enrollment. Note: Colposcopy and cervical

2018 Clinical Trials

163. Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

At Screening and Enrollment, agrees not to participate in other research studies involving drugs, medical devices, vaginal or rectal products, or vaccines after the Screening Visit and for the duration of study participation Exclusion Criteria: Pregnant at Screening or Enrollment or plans to become pregnant during the study period Note: A documented negative pregnancy test performed by study staff is required for inclusion; however, a self-reported pregnancy is adequate for exclusion from the study (...) outcome less than 90 days prior to Enrollment Gynecologic or genital procedure (e.g., tubal ligation, dilation and curettage, piercing) 45 days or less prior to Enrollment Note: Colposcopy and cervical biopsies for evaluation of an abnormal Pap test as well as IUD insertion/removal are not exclusionary. Currently breastfeeding or planning to breastfeed during the study Participation in any other research study involving drugs, medical devices, vaginal or rectal products, or vaccines, in the 60 days

2018 Clinical Trials

164. In-use Study of Four Different Tampons

, neutropenia, autoimmune disease, major depression or any other medical condition, which in the opinion of the Investigator would preclude study participation (exception...stable dose of Thyroid medication for at least 6 months prior to enrollment); having a vaginal probiotic therapy (self-reported) have participated in a clinical study with exposure to any investigational drug product within 30 days prior to this study; have a vaginal erythema grade of ≥2.0 and/or the presence of abrasions (...) 6 months; are pregnant (per urine pregnancy test at screening), or intend to become pregnant in the next 5 months; have a history of Toxic Shock Syndrome (TSS); have a history of heart valve replacement; have had an abnormal Pap in either of your last 2 Pap Smears; have taken steroids (systemic and/or topical), corticosteroids, antihistamines, and/or anti-inflammatories within the past seven days (excludes hormonal contraception); have a history of immunosuppressive drug therapy, chemotherapy

2018 Clinical Trials

165. Cantharidin and Occlusion in Verruca Epithelium

, using the VP-102 applicator. Drug: VP-102-cantharidin topical film forming solution VP-102 cantharidin topical film forming solution. Other Name: Subjects will receive treatment to their warts with VP-102 Device: VP-102 Applicator The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device. Outcome Measures Go to Primary Outcome Measures : Cohort 1-Proportion of subjects exhibiting complete clearance of all (...) Consulting, Inc. Paidion Research, Inc. BioClinica, Inc. Information provided by (Responsible Party): Verrica Pharmaceuticals Inc. Study Details Study Description Go to Brief Summary: This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts. Condition or disease Intervention/treatment Phase Common Wart

2018 Clinical Trials

166. A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

history of abnormal Pap test. History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer. Undergone hysterectomy (either vaginal or total abdominal hysterectomy). Receiving or has received in the year prior to Day 1 vaccination an excluded immunosuppressive therapy. A participant will be excluded if she is currently receiving steroid therapy, has recently received such therapy, or has received 2 or more courses (...) (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Actual Study Start Date : August 31, 2018 Estimated Primary Completion Date : April 21, 2019 Estimated Study Completion Date : October 19, 2023 Resource links provided by the National Library of Medicine available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Chinese Girls Aged 9 to 19 Years Participants will receive V501 0.5 mL intramuscular injection at Day

2018 Clinical Trials

167. Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections

in the test areas that would interfere with the assessments of this study. Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune. Individuals who have a pre-existing or dormant dermatologic condition (e.g., psoriasis, atopic dermatitis, rosacea, skin cancer, etc.) Individuals who require electrolysis, waxing, or use depilatories on the face during conduct of the study. Individuals with any planned surgeries and/or invasive medical (...) Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections Actual Study Start Date : June 4, 2018 Actual Primary Completion Date : December 3, 2018 Actual Study Completion Date : December 3, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment Group #1 Subject in Treatment group 1 will apply the following products in the morning and evening. SkinMedica

2018 Clinical Trials

168. Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

for at least the two months prior to Enrollment. Per participant report at Screening, willing to abstain from inserting anything into the vagina for 72 hours prior to each study visit, including receptive intercourse. Note: In the event the VR has been expelled and requires reinsertion, repositioning the VR is permitted. Note: Participant use of tampons is permitted at any time during the study. At Screening and Enrollment, agrees not to participate in other research studies involving drugs, medical (...) (BV) and asymptomatic candidiasis — are offered treatment consistent with WHO recommendations. If treatment is completed and symptoms have resolved within 70 days of obtaining informed assent/consent for screening, the participant may be enrolled. Genital warts requiring treatment also must be treated prior to enrollment. Genital warts requiring therapy are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance, or physical

2018 Clinical Trials

169. Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Study Start Date : September 25, 2018 Actual Primary Completion Date : January 2, 2019 Actual Study Completion Date : January 2, 2019 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment A 2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72 Drug: AZD0914 Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder (...) male or female subjects, aged 18 to 45 years inclusive, to evaluate the effect of zoliflodacin on the corrected QT interval of the electrocardiogram (ECG) using Fridericia's Formula (QTcF) and other ECG parameters; the correlation of the drug concentrations (and pharmacokinetic (PK) profile) with time-matched, placebo-corrected, baseline-adjusted difference in QTcF interval (delta delta QTcF); and the PK and safety profiles of the new zoliflodacin formulation. Each subject will receive one dose

2018 Clinical Trials

170. Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

on the basis of medical history, physical examination (if deemed necessary), and laboratory testing Subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes. Exclusion Criteria: Subject has a history of an abnormal Pap test or abnormal cervical biopsy results (showing cervical intraepithelial neoplasia or worse) or cervical disease (i.e., surgical treatment for cervical lesions). Subject has history of genital warts, Vulvar (...) the results of the study or pose an additional risk to the subject. Patient's medication Exclusion criterion only for HIV patients: Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (tumour necrosis factor-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin, antilymphocyte sera, or other

2018 Clinical Trials

171. VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions. Condition or disease (...) licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay; NOTE: A ?licensed? assay refers to a U.S. Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studies Must be documented to be on an effective combination antiretroviral therapy (ART) regimen, generally a 3-drug regimen based

2018 Clinical Trials

172. Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

Angeles Collaborator: Cedars-Sinai Medical Center Information provided by (Responsible Party): Anna-Barbara Moscicki, MD, University of California, Los Angeles Study Details Study Description Go to Brief Summary: Background: Prevention of cervical cancer and genital warts could be achieved by immunization with the prophylactic human papillomavirus (HPV) vaccines commercially available. However, in the U.S. only 38% of females and 14% of males in the recommended age group (9-26 years) receive (...) Messaging via SMS Behavioral: CDC Health Pamphlets Not Applicable Detailed Description: Prevention of cervical cancer and genital warts could be achieved by immunization with the prophylactic human papillomavirus (HPV) vaccines commercially available. However, in the U.S. only 38% of females and 14% of males in the recommended age group (9-26 years) receive the complete, three-dose HPV vaccine. Because the HPV vaccine is covered under the Vaccine for Children Program, the underinsured and uninsured have

2018 Clinical Trials

173. A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

13) Use of any prescription medication within 30 days before dosing or planned use during the study period except as noted below and approved by the designated study clinician Note 1: Prohibited medications include moderate or strong CYP3A4 inducers; antibiotics; injectable or oral antidiabetic drugs; anti-lipid drugs; immunosuppressive agents; immune modulators; oral corticosteroids; anti-neoplastic agents; any vaccine (licensed or investigational) except licensed influenza vaccine during (...) , 2018 Actual Study Completion Date : March 2, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Zoliflodacin 4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8 Drug: AZD0914 Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent Outcome Measures Go to Primary Outcome Measures : Maximum Observed Concentration

2018 Clinical Trials

174. Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasiv

(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT. Actual Study Start Date : December 7, 2018 Estimated Primary Completion Date : March 29, 2019 Estimated Study Completion Date : March 29, 2019 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort (...) of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Sampling Method: Non

2018 Clinical Trials

175. The use of vaccines in HIV-positive adults

a booster dose every 10 years if at risk of exposure, typically through travel [1C] • We recommend that individuals who may be occupationally exposed to diphtheria (e.g. laboratory workers) be tested for diphtheria antibodies 3 months after vaccination to confirm protective immunity, and be revaccinated if required [1C] • We recommend that following a credible or confirmed exposure to diphtheria, HIV-­-positive contacts receive post-­-exposure prophylaxis with antibiotic therapy and vaccination (...) a profoundly immunocompromised patient (CD4 cell count 8%). Regions of low prevalence include Western, Northern and Central Europe, North America, and Australia. Worldwide, the risk of infection is increased in injecting drug users (IDUs), men who have sex with men (MSM), those with multiple sexual partners, household and other close contacts of HBV-­-infected persons, those receiving blood or blood products, patients and staff of haemodialysis centres, people sharing unsterile medical and dental equipment

2015 British HIV Association

176. Prevention of skin cancer

for Research in Operative Medicine (IFOM), University of Witten/Herdecke • Dr. Barbara Buchberger, MPH, Dr. Romy Heymann, Chair of Medical Management, University of Duisburg-Essen. 1.10.5. Translation The document was translated by mt-g medical translation GmbH & Co. KG, Ulm, reviewed by the Association of Dermatological Prevention (ADP). 1.11. General remarks on the terminology used Gender In the interest of greater legibility, the use of the masculine and feminine forms at the same time will be avoided (...) 10 1.10.1. Co-ordination and project team 10 1.10.2. Professional societies and organisations involved 10 1.10.3. Patient involvement 13 1.10.4. Methodological support 13 1.10.5. Translation 14 1.11. General remarks on the terminology used 14 2. Introduction 15 2.1. Scope and objective 15 2.1.1. Aim and problem statement 15 2.1.2. Target audience 16 2.2. Interface with the evidence-based guideline on diagnosis, therapy and follow-up of melanoma 16 2.3. Period of validity and update process 17 2.4

2014 German Guideline Program in Oncology

177. Squamous cell carcinoma

a spectrum of genetic defects in DNA repair, are characterized by multiple and early cSCCs. Apart from genetic syndromes with deficiencies of the protective mechanisms against UVR, 10 other inherited conditions such as epidermodysplasia verruciformis, a genetic disorder with a defect in the protection against HPV is also associated with a high rate of cSCC. Therapeutic agents can also promote the development and progression of cSCCs. Immune suppression, including allogeneic organ transplantation, therapy (...) of Barcelona; IDIBAPS and CIBER de enferme- dades raras, Spain 5 University Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brus- sels, Belgium 6 University Department of Dermatology, Vienna, Austria 7 Istituto di Clinica Dermosifilopatica, Università Cattolica del Sacro cuore, Rome, Italy 8 Institute for translational Dermato-Oncology, German Cancer Research Center, Medical Uni- versity of Essen, Germany 9. Department of Dermatology and Venerology, Medical University of Graz

2014 European Dermatology Forum

178. UK national guideline for the management of Genital Molluscum in adults

manifestations in paediatric HIV/AIDS patients in Mulago Hospital, Uganda. Afr Health Sci 2003; 3(2): 83-86. 75. Robinson MR, Udell IJ, Garber PF, et al. Molluscum contagiosum of the eyelids in patients with acquired immune deficiency syndrome. Ophthalmology 1992; 99(11): 1745-47. 76. Cursiefen C, Grunke M, Dechant C, et al. Multiple bilateral eyelid Molluscum Contagiosum lesions associated with TNFA-antibody and Methotrexate therapy. Am J Ophthamol 2002; 134(2): 270-71. 77. Margo C, Katz NN. Management (...) treatment with CO2 laser, trichloroacetic acid and pulsed dye laser. Lasers Surg Med 2000; 27(4), 291-94. 81. Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with Highly Active Anti-Retroviral Therapy (HAART) in patients with AIDS. Eur J Dermatol 1999; 9(3): 211-13. 82. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1(2): 107-15. 83. Ratnam

2014 British Association for Sexual Health and HIV

179. Management of molluscum contagiosum

. 36,51,56,57 Severe molluscum infections were also common in HIV patients in the pre-highly active antiretroviral therapy (HAART) era, 58,59 estimated to a?ect 5–18% of positive individuals. 60–63 Extensive disease usually occurs in the setting of late HIV, with CD4 counts sig- ni?cantly under 200 and concurrent illnesses related to advanced HIV infection. 45,61,64–72 Extensive molluscum may be the ?rst indication of HIV disease. 45 Lesionsoccurcommonlyonthefaceandneck, 49,73 but can sometimes a?ect (...) the genital regions, indicating both venereal and non-venereal spread in this scenario. 45 Particularly in immunocompromise, molluscum lesions cana?ecttheeyelids 74–76 andcausechronicconjunctivitis duetoaforeignbody-typereaction. 14,75,77–79 Molluscum infectioncanbeparticularlydi?culttotreatinlate-stage HIV using conventional means, 62,80 though usually responding to HIV antiretroviral treatment (ARV) initi- ation. 81 However, an immune reconstitution in?amma- tory syndrome (IRIS) reaction to molluscum

2014 British Association for Sexual Health and HIV

180. HIV, viral hepatitis and STIs - a guide for primary care

Liver Association (ALA), The Australasian Sexual Health Alliance (ASHA) , the Australian College of Rural and Remote Medicine (ACCRM), the Australasian Society for Infectious Diseases (ASID), the Australian Federation of AIDS Organisations (AFAO), the National Association of People Living with HIV Australia (NAPWHA), Australian Injecting & Illicit Drug Users League (AVIL), Australasian Sexual Health and HIV Nurses Association (ASHHNA), the Australian Indigenous Doctors Association (AIDA (...) REVIEw Mark Danta Associate Professor of Medicine, St Vincent’s Clinical School, Faculty of Medicine, UNSW Australia, Sydney NSW Lynne Wray Clinical Services Manager and Senior Staff Specialist, Sydney Sexual Health Centre, Sydney Hospital, Sydney NSW 2008 EDITION Joe Sasadeusz Head of Medical Virology, Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne Vic Stephen Locarnini Head of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory

2014 Clinical Practice Guidelines Portal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>